What issues should be paid attention to when taking trametinib?

Trametinib/Megenin , as a MEK inhibitor, has clear efficacy in the treatment of BRAF V600 mutated melanoma, non-small cell lung cancer, and thyroid cancer. The method and timing of its administration are crucial to the stability of the drug effect and the control of side effects. The correct frequency of medication is not only related to the therapeutic effect, but also can effectively avoid toxic reactions caused by fluctuations in blood drug concentration. According to international guidelines and manufacturer recommendations, trametinib should be taken orally once daily. The recommended dose is 2 mg. The tablet should be swallowed whole and should not be chewed, broken or crushed.

Taking it on an empty stomach is a key requirement for trametinib treatment. Specifically, patients need to take it at least 1 hour before eating or 2 hours after eating to avoid the impact of food on drug absorption. High-fat or high-protein diets may interfere with the gastrointestinal absorption efficiency of drugs, thereby affecting their active distribution and target binding ability in the body. Maintaining a stable fasting environment can ensure that the drug enters the body circulation at a constant rate and achieves optimal drug release.

In addition, in order to maintain a constant blood concentration, trametinib should be taken at approximately the same time every day to avoid peak and valley changes in the drug concentration in the body caused by time inconsistency, which in turn affects the continued inhibition of the MEK pathway. If a dose is missed and the next dose is less than 12 hours away, the missed dose should be skipped. It is not recommended to take supplementary doses or superimpose medications.

During the course of medication, if symptoms such as persistent fever, rash, diarrhea, difficulty breathing, blurred vision, etc. occur, you should be alert to possible adverse reactions related to trametinib, especially cardiac function or eye toxicity. In this case, the attending physician should be contacted promptly to evaluate whether to adjust the dose or conduct a treatment interruption. At the same time, you should avoid drinking grapefruit juice and other drinks that may interfere with the CYP enzyme system during medication, so as not to affect the metabolic pathway of trametinib.

Reference materials:https://go.drugbank.com/drugs/DB08911